Literature DB >> 33236203

The role of obstructive sleep apnea on the prognosis of pulmonary embolism: a systemic review and meta-analysis.

Jiahuan Xu1,2, Xingjian Wang2, Fanqi Meng2, Tian Zhao1, Tingyu Tang1, Wenjuan Wu1, Wei Wang3.   

Abstract

PURPOSE: The relationship between obstructive sleep apnea (OSA) and pulmonary embolism (PE) has been reported by some studies but the underlying mechanism remains unclear. We aimed to systematically assess the role of OSA on the disease prognosis of PE.
METHODS: We searched for studies on the relationship of OSA and the prognosis of PE published up to February 2020 among PubMed, Web of Science, EMBASE, and Cochrane Library databases. Two independent reviewers conducted the process of study search and screening, quality assessment, and data extraction. Meta-analysis was carried out using RevMan 5.3.
RESULTS: A total of 9 articles were included, and the funnel plots suggested no evidence of publication bias among studies. The results showed that compared to PE patients without OSA, the PE patients with moderate-severe OSA were more likely to be high-risk type (OR = 1.96, 95% CI [1.14, 3.34]) and with higher index of disease severity (sPESI: OR = 2.29, 95% CI [1.50, 3.47]; PAOI%: MD = 13.52, 95% CI [7.2, 19.83]). The prevalence of recurrent PE was higher in PE patients with OSA than those without OSA (RR = 3.87, 95% CI [1.65, 9.07]). However, there was no significant difference in right ventricle to left ventricle short-axis diameter (MD = 0.08, 95% CI [- 0.06, 0.21]), length of hospital stay (MD = 1.03, 95% CI [- 1.11, 3.17]), or prevalence of deep vein thrombosis (OR = 0.87, 95% CI [0.48, 1.57]). Sensitivity and subgroup analysis showed that the pooled outcomes were stable.
CONCLUSION: OSA, especially moderate-severe OSA, was a risk factor for high-risk PE and recurrent PE. However, the current evidence showed that the length of hospital stay is not influenced by OSA.
© 2020. Springer Nature Switzerland AG.

Entities:  

Keywords:  Meta-analysis; Obstructive sleep apnea; Prognosis; Pulmonary embolism

Mesh:

Year:  2020        PMID: 33236203     DOI: 10.1007/s11325-020-02258-z

Source DB:  PubMed          Journal:  Sleep Breath        ISSN: 1520-9512            Impact factor:   2.816


  3 in total

1.  [Effect of obstructive sleep apnea on the severity of acute pulmonary thromboembolism].

Authors:  Y Xiao; L R Yang; G F Zhu; Y Zhang; C T Wu; W M Zhang
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2019-03-12

2.  Effects of somatotropic axis on cognitive dysfunction of obstructive sleep apnea.

Authors:  Jiahuan Xu; Zheng Qin; Wenyang Li; Xiaomeng Li; Hui Shen; Wei Wang
Journal:  Sleep Breath       Date:  2019-05-09       Impact factor: 2.816

3.  [Obstructive sleep apnea-hypopnea syndrome in patients with pulmonary thromboembolism: clinical features and management].

Authors:  Xiang-feng Zhang; Yuan-ming Gao; Guang-fa Zhu; Jing-hua Yang; Shao-fang Ding; Shuang Liu
Journal:  Zhonghua Jie He He Hu Xi Za Zhi       Date:  2012-03
  3 in total
  4 in total

1.  Globular adiponectin protects hepatocytes against intermittent hypoxia-induced injury via Pink1/Parkin-mediated mitophagy induction.

Authors:  Wenxiao Ding; Yanbin Dong; Xilong Zhang
Journal:  Sleep Breath       Date:  2021-10-26       Impact factor: 2.655

2.  Translation and validation of the STOP-Bang questionnaire into Slovene.

Authors:  Andrej Pangerc; Marija Petek Šter; Leja Dolenc Grošelj
Journal:  Eur J Med Res       Date:  2021-04-07       Impact factor: 2.175

Review 3.  Obstructive Sleep Apnea as a Risk Factor for Venous Thromboembolism: A Systematic Review.

Authors:  Rhea Raj; Akil Paturi; Mohamed A Ahmed; Sneha E Thomas; Vasavi Rakesh Gorantla
Journal:  Cureus       Date:  2022-02-28

4.  Sex-differences in the effect of obstructive sleep apnea on patients hospitalized with pulmonary embolism and on in-hospital mortality.

Authors:  Rodrigo Jiménez-García; Ana López-de-Andrés; Javier de-Miguel-Diez; Marta Lopez-Herranz; Valentín Hernandez-Barrera; David Jimenez; Manuel Monreal
Journal:  Sci Rep       Date:  2021-09-15       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.